The company said its products are also informing surgery and treatment decision-making using the same minimally invasive patient sample, according to a statement.
"Our RNA platform uniquely enables our Afirma offering to answer important clinical questions that can guide various points in a patient's journey, helping to improve outcomes," CEO Bonnie Anderson said. "Further, by providing this comprehensive information from the original biopsy used in diagnosis, we can streamline workflows and enable patients to get the answers they need faster and more easily."
Shares rose by more than 3% intraday.
Price: 28.42, Change: +0.85, Percent Change: +3.10
|Analyst Actions: UBS Lifts Price Target on Surgery P...|
|Analyst Actions: Craig-Hallum Lifts Inphi's Price Ta...|
|Analyst Actions: Cowen Lifts Inphi's Price Target to...|
|Analyst Actions: DA Davidson Raises Inphi's Price Ta...|
|Skyhawk Unveils 2nd Collaboration With Celgene Affil...|